company background image
EDIT

Editas Medicine NasdaqGS:EDIT Stock Report

Last Price

US$10.06

Market Cap

US$676.6m

7D

-3.0%

1Y

-66.5%

Updated

01 Dec, 2022

Data

Company Financials +
EDIT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

EDIT Stock Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

Editas Medicine, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Editas Medicine
Historical stock prices
Current Share PriceUS$10.06
52 Week HighUS$32.37
52 Week LowUS$9.59
Beta1.96
1 Month Change-21.10%
3 Month Change-32.17%
1 Year Change-66.50%
3 Year Change-66.90%
5 Year Change-60.98%
Change since IPO-44.73%

Recent News & Updates

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Recent updates

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25
Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17
Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?

Sep 07
Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Aug 12
Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

We're Not Very Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Apr 29
We're Not Very Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Chairman James Mullen Just Bought 250% More Shares In Editas Medicine, Inc. (NASDAQ:EDIT)

Mar 05
Chairman James Mullen Just Bought 250% More Shares In Editas Medicine, Inc. (NASDAQ:EDIT)

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 11%

Feb 27
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 11%

Could The Editas Medicine, Inc. (NASDAQ:EDIT) Ownership Structure Tell Us Something Useful?

Feb 12
Could The Editas Medicine, Inc. (NASDAQ:EDIT) Ownership Structure Tell Us Something Useful?

What Does The Future Hold For Editas Medicine, Inc. (NASDAQ:EDIT)? These Analysts Have Been Cutting Their Estimates

Jan 21
What Does The Future Hold For Editas Medicine, Inc. (NASDAQ:EDIT)? These Analysts Have Been Cutting Their Estimates

This Insider Has Just Sold Shares In Editas Medicine, Inc. (NASDAQ:EDIT)

Jan 15
This Insider Has Just Sold Shares In Editas Medicine, Inc. (NASDAQ:EDIT)

Here's Why We're Not At All Concerned With Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Jan 01
Here's Why We're Not At All Concerned With Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Did Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Sell Shares?

Dec 06
Did Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Sell Shares?

Shareholder Returns

EDITUS BiotechsUS Market
7D-3.0%2.7%1.4%
1Y-66.5%-10.3%-16.1%

Return vs Industry: EDIT underperformed the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: EDIT underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is EDIT's price volatile compared to industry and market?
EDIT volatility
EDIT Average Weekly Movement11.4%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: EDIT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: EDIT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013264Gilmore O’Neillhttps://www.editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.

Editas Medicine, Inc. Fundamentals Summary

How do Editas Medicine's earnings and revenue compare to its market cap?
EDIT fundamental statistics
Market CapUS$676.63m
Earnings (TTM)-US$201.13m
Revenue (TTM)US$25.65m

26.4x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EDIT income statement (TTM)
RevenueUS$25.65m
Cost of RevenueUS$160.51m
Gross Profit-US$134.87m
Other ExpensesUS$66.26m
Earnings-US$201.13m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.99
Gross Margin-525.90%
Net Profit Margin-784.29%
Debt/Equity Ratio0%

How did EDIT perform over the long term?

See historical performance and comparison